Cholesterol & Lipid

Sort by:
Relevance Thumbs Up Comments Views Newest Oldest
10:53

ASPC 2020 Virtual Summit on CVD Prevention

ASPC CVD Prevention Panel Discussion: How Can We Educate Our Patients to Prevent CVD? What Happens With Atherosclerotic Plaque/Calcium Density in Menopause? How to Diagnose CMD When We Don’t Have All Available Technologies?

FEATURING Leslee Shaw, Nanette Wenger, Viviany Taqueti, Renee Bullock-Palmer, Erin Michos, Martha Gulati, Pam Taub
  • 18 views
  • March 17, 2021
27:57

ASPC 2020 Virtual Summit on CVD Prevention

100 Years from C-Reactive Protein to Anti-Inflammatory Therapy for Atherosclerosis: A Brief History of Epidemiologic Discovery

FEATURING Paul Ridker
  • 60 views
  • March 16, 2021
  • 1
28:45

ASPC 2020 Virtual Summit on CVD Prevention

Apolipoprotein B & CVD Risk: How Can We Improve CVD Prevention With a Long-Term apoB Model? What Are the Benefits/Value of apoB? Why There Is apoB Resistance in the US vs. Europe?

FEATURING Allan Sniderman
  • 362 views
  • March 16, 2021
  • 5
07:13

ASPC 2020 Virtual Summit on CVD Prevention

FH Visual Aids in Patient Education Research Highlights: Can Distribution of Visual Educational Materials Significantly Increase Referral for Identification & Treatment of Probable FH Patients?

FEATURING David M. Harmon
  • 16 views
  • March 16, 2021
27:34

ASPC 2020 Virtual Summit on CVD Prevention

Atherosclerosis & MicroRNAs: How MicroRNAs Impacts Risk for Atherogenesis?

FEATURING Peter Toth
  • 94 views
  • March 16, 2021
  • 1
37:24

ASPC 2020 Virtual Summit on CVD Prevention

Primary Prevention by CAC vs. CTA: Which One Is Better and Why? - SCCT Expert Debate

FEATURING James Min, Khurram Nasir
  • 39 views
  • March 16, 2021
20:21

ASPC 2020 Virtual Summit on CVD Prevention

Discussion on CTA/CAC for Primary Prevention, Genetic Testing, LDL Mutations, and Implementation of FIND FH Into Clinical Care - 2020 ASPC Virtual Summit on CVD Prevention

FEATURING Ron Blankstein, Salim Virani, Arthur Agatston, James Min, Samip Sheth, Khurram Nasir, Amit Khera
  • 24 views
  • March 16, 2021
14:00

ASPC 2020 Virtual Summit on CVD Prevention

Genetic Testing in Preventive Cardiology: Are Those With FH Mutation, for Any Given Observed LDL, at Higher Risk for CAD? Who to Test for FH, and What Are the Ordering Considerations?

FEATURING Amit Khera
  • 356 views
  • March 12, 2021
  • 3
14:55

ASPC 2020 Virtual Summit on CVD Prevention

Statin Usage in Athletes: Is There Increased Muscle Injury With Statins Usage? Can They Reduce Exercise Training Response? What Are the Administration Recommendations?

FEATURING Paul D. Thompson
  • 22 views
  • March 12, 2021
27:36

ASPC 2020 Virtual Summit on CVD Prevention

Sex Differences in Atherosclerosis: Is There a Sex Specific Phenotype for Atherosclerotic Plaque? Can Antiplatelet Therapy & Statins Improve CVD Outcomes?

FEATURING Leslee Shaw
  • 29 views
  • March 12, 2021
16:05

ASPC 2020 Virtual Summit on CVD Prevention

Polypill for CVD Prevention: When Is Polypharmacy Appropriate? Can Rosuvastatin + Candesartan + HCTZ Reduce CV Events?

FEATURING Keith Ferdinand
  • 164 views
  • March 12, 2021
  • 1
18:02

San Diego Heart Failure Symposium for Primary Care and Internal Medicine Physicians

Novelties in Lipid Lowering Therapies: Can Statin Therapy Reduce Residual Risk? How Promising Are Icosapent Ethyl, Bampedoic Acid, Inclisiran and Evinacumab for Treating the Patients?

FEATURING Pam Taub
  • 925 views
  • February 5, 2021
  • 11
39:29

37th Annual Advances in Heart Disease

Contemporary Approach for Managing PAD: What Are the Guideline Recommended Therapies? What Is the Efficacy of Statin Therapy, PCSK9 Inhibitors, Antiplatelet Agents and Anticoagulants?

FEATURING Mark Creager, Binh An Phan
  • 259 views
  • February 4, 2021
  • 2
22:01

University of Colorado Department of Medicine

NAFLD Epidemiology & Diagnosis: When to Screen? What Are the Indications for Transplantation? Is Statin Therapy Safe for NAFLD/NASH?

FEATURING Amanda Wieland
  • 81 views
  • February 2, 2021
08:30

University of Colorado Department of Medicine

NAFLD Pharmacologic Management: What Are the Benefits & Safety Concerns of Vitamin E and Pioglitazone? What Is the Efficacy of OCA?

FEATURING Amanda Wieland
  • 126 views
  • February 2, 2021
35:46

37th Annual Advances in Heart Disease

Lipoprotein(a) and CVD: Do Elevated Lp(a) Levels Contribute to CVD Risk? What Are the Effects of Statins, PCSK9-i, LDL Apheresis and ASOs Therapies?

FEATURING Binh An Phan, Peter Ganz
  • 1,823 views
  • January 29, 2021
  • 16
19:46

Cardiometabolic Health Congress (CMHC)

ASCVD Risk Reduction Recommendations: Who Benefits From High Intensity Statins? Which Non-Statin Therapies to Choose? What Is the Efficacy of Inclisiran in Patients With Elevated LDL Cholesterol?

FEATURING Margo Minissian
  • 165 views
  • January 18, 2021
  • 1
17:57

Cardiometabolic Health Congress (CMHC)

CMHC Tsunami Expert Discussion on Nutrition, Insulin Therapy, Practical Tips for Telemedicine, and the Link Between Hyperinsulinemia & Atherosclerosis

FEATURING Margo Minissian, Robert Eckel, Keith Ferdinand
  • 60 views
  • January 15, 2021
19:30

Cardiometabolic Health Congress (CMHC)

Lipids/BP & ASCVD Risk Reduction Guidelines: What Are the Nutrition and Lifestyle Recommendations? How to Implement SGLT2i for CV Disease in T2DM?

FEATURING Margo Minissian
  • 245 views
  • January 15, 2021
24:35

Keck School of Medicine of USC

Role of Lipoprotein(a) in Coronary Disease: What CV Risks Can you Expect? How to Manage the Condition?

FEATURING Steven Nissen
  • 947 views
  • January 5, 2021
  • 13
18:33

Cardiometabolic Health Congress (CMHC)

59 y/o Male With Hypertension, Diabetes, CKD, Obesity, and Hypercholesterolemia: What Would Be an Optimal Consideration for the Clinical Care?

FEATURING Ileana Pina, Javed Butler, Matthew Weir
  • 304 views
  • December 21, 2020
  • 3
09:23

26th Annual San Diego Heart Failure Symposium

Q&A: Treating Hyperlipidemia, PAH and Other CV Diseases

FEATURING Barry Greenberg, Pam Taub, Daniel Blanchard, atul malhotra, Nick Kim
  • 33 views
  • December 16, 2020
15:21

26th Annual San Diego Heart Failure Symposium

Advances in Treating Hyperlipidemia: What Are the Results of Trials with PCSK9 Inhibitors and Icosapent Ethyl? What Are the Benefits of Bempedoic Acid and Inclisiran?

FEATURING Pam Taub
  • 974 views
  • December 15, 2020
  • 9
37:38

Nadir Ali

Lipotoxicity With Low Carbohydrate Diets: Can Obese and Insulin-Resistant Individuals Safely Consume a High-Fat Diet?

  • 871 views
  • December 14, 2020
  • 4
20:51

Nadir Ali

Cholesterol & Lipoprotein Regulation: Are High Cholesterol and LDL Beneficial in Infection/Inflammation Protection?

  • 697 views
  • December 14, 2020
  • 4

Cholesterol & Lipid

Recommended Topics:

PCSK9

All Topics: